Ventyx Biosciences, INC Form 4 insider transactions
Ventyx Biosciences' Chief Scientific Officer, John Nuss, sold 21,119 shares of common stock at an average price of $2.36 per share on December 27, 2024.
Sheila Gujrathi, a director at Ventyx Biosciences, purchased 130,000 shares of common stock at an average price of $2.3121 per share.
Ventyx Biosciences' Chief Scientific Officer, John Nuss, acquired and sold shares to cover tax obligations related to vesting restricted stock units.
Ventyx Biosciences CEO, Raju Mohan, acquired 116,668 shares of common stock through the vesting of restricted stock units.
John Nuss, Chief Scientific Officer of Ventyx Biosciences, exercised stock options to acquire a total of 198,934 shares of common stock at a price of $0.20 per share.
Ventyx Biosciences CEO, Raju Mohan, has acquired a total of 500,000 shares in the company through open market purchases.
Mark S. Forman, Chief Medical Officer of Ventyx Biosciences, Inc., reports the acquisition of stock options.
NSV Partners III LP reports the distribution of Ventyx Biosciences (VTYX) shares to its limited partners, resulting in a change in beneficial ownership.
Somu Subramaniam, a director and 10% owner of Ventyx Biosciences, reports the distribution of shares from NSV Investments to its limited partners, resulting in a change in beneficial ownership.
CEO Raju Mohan exercised stock options and disposed of 96,778 common stock shares at $0.2 on June 10, 2024, according to a Form 4 filing.
Director William White of Ventyx Biosciences acquired 33,000 stock options at an exercise price of $3.285 on June 6, 2024, as reported in a Form 4 filing with the SEC.
Director Onaiza Cadoret-Manier acquired 33,000 stock options in Ventyx Biosciences on June 6, 2024, according to a recent SEC filing.
Director Sheila Gujrathi acquired 33,000 stock options in Ventyx Biosciences, Inc. at an exercise price of $3.285 on June 6, 2024.
Director Allison Hulme acquired 33,000 stock options in Ventyx Biosciences, Inc. on June 6, 2024, according to a Form 4 filing.
Director Somu Subramaniam of Ventyx Biosciences acquired 33,000 stock options on June 6, 2024, according to a Form 4 filing with the SEC.
Chief Operating Officer of Ventyx Biosciences, Matthew Richard Moore, reports acquisition of stock options.
Director Somu Subramaniam reports the distribution of shares from NSV Investments III, L.P. and indirect beneficial ownership of Ventyx Biosciences, Inc. shares.
NSV Partners III LP reports a pro rata distribution of 695,339 common stock shares of Ventyx Biosciences to its limited partners on April 12, 2024, resulting in a decrease in direct ownership but maintaining significant indirect beneficial ownership.
Christopher Krueger, Chief Business Officer of Ventyx Biosciences, sold 1,651 shares of common stock to cover tax obligations related to vesting restricted stock units.
John Nuss, Chief Scientific Officer of Ventyx Biosciences, sold 1,651 shares of common stock on April 2, 2024, to cover tax obligations related to vesting restricted stock units.
CEO Raju Mohan sold 4,312 shares of Ventyx Biosciences stock to cover tax obligations related to vesting restricted stock units.
Martin Auster, CFO of Ventyx Biosciences, sold 1,405 shares of common stock to cover tax obligations related to vesting restricted stock units.
Christopher Krueger, Chief Business Officer of Ventyx Biosciences, reports the exercise of stock options and subsequent changes in beneficial ownership.
Martin Auster, CFO of Ventyx Biosciences, reports the vesting and subsequent disposal of restricted stock units on March 28, 2024.
CEO Mohan Raju reports the vesting of restricted stock units into common stock of Ventyx Biosciences.
Chief Scientific Officer John Nuss of Ventyx Biosciences reports the vesting of restricted stock units, resulting in the acquisition of 4,531 shares of common stock.